Axsome Therapeutics

Axsome Therapeutics, Inc. engages in the development of novel therapies for the management of central nervous system disorders. Its product candidates include AXS-05, AXS-07, AXS-12, and AXS-14 which are being developed for multiple pain and primary care indications. The company was founded by Herriot Tabuteau on January 12, 2012 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Axsome Therapeutics reports robust Q4 performance and eyes global expansion

Axsome Therapeutics had a strong Q4 2022, driven by successful commercialization of Auvelity and Sunosi.
While facing challenges such as legal disputes and payer coverage, the company is well-positioned for growth.
Strategic opportunities in expanding product portfolio and market access present avenues for future success.
Financially stable with a focus on innovation, Axsome is poised for continued growth and market expansion.

Axsome Therapeutics excels in Q1 2023 despite financial hurdles

Axsome Therapeutics demonstrated strong commercial and pipeline progress in Q1 2023, despite financial challenges.
The company's focus on expanding market share and optimizing commercial operations bodes well for future growth.
While facing challenges in sales guidance and NDA filings, Axsome's strong financial position and product performance offer opportunities for sustained success.

Axsome Therapeutics reports robust Q2 sales and expands product portfolio

Axsome Therapeutics demonstrated strong sales performance driven by Auvelity and Sunosi, with a focus on future growth potential.
Despite challenges such as increased costs and a net loss, the company is strategically expanding its product portfolio and market reach.
Opportunities lie in new FDA indications for existing products and the goal to have five marketed products by 2025.

Axsome Therapeutics reports robust Q3 earnings and outlines growth strategies

Axsome Therapeutics delivered strong revenue growth in Q3 2023, driven by Auvelity and Sunosi, showcasing a promising commercial outlook.
The company's pipeline progress and upcoming milestones reflect a commitment to innovation and expansion in the CNS therapeutic space.
While challenges like ongoing losses and strategic resource allocation persist, opportunities in new markets and product diversification offer avenues for future growth.

Axsome Therapeutics reports robust 2023 performance and eyes growth opportunities

Axsome Therapeutics had a strong financial performance in 2023, driven by the success of Auvelity and Sunosi. Despite challenges like increased expenses and net loss, opportunities for growth exist through new indications and expanded payer coverage.

Axsome Therapeutics excels in Q1 2024, poised for growth

Axsome Therapeutics demonstrated exceptional financial growth and pipeline advancements in Q1 2024, particularly in neuroscience programs like AXS-12.
Strong commercial performance of Auvelity and Sunosi, coupled with stable payer coverage and growth strategies, underpin the company's success trajectory.
While facing challenges related to study timelines and cybersecurity, Axsome Therapeutics remains poised to capitalize on upcoming milestones and market opportunities.

Axsome Therapeutics excels in Q2 2024, eyes market expansion

Axsome Therapeutics delivered a strong performance in Q2 2024, driven by revenue growth and progress on key product developments.
While facing challenges in market competition and operational execution, the company remains optimistic about future prospects.
Strategic opportunities in market expansion and product innovation position Axsome well for sustained growth and success in the CNS treatment space.

Axsome Therapeutics excels in Q3 with record revenue and pipeline progress

Axsome Therapeutics delivered a strong performance in Q3 2024, surpassing $100 million in quarterly product revenue and maintaining a solid financial position.
The company's strengths lie in its successful products, robust pipeline, and strategic commercial initiatives, supported by a strong cash reserve.
Challenges include managing expenses, navigating market dynamics, and sustaining commercial momentum, while opportunities exist in product launches and market expansion.
Overall, Axsome's performance reflects a balanced approach to growth, innovation, and market competitiveness, positioning the company for continued success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which engages in the development of novel therapies for the management of central nervous system disorders. Its portfolio consists of Products Overview and Pipeline Overview. The Products Overview includes Auvelity and Sunosi. The Pipeline Overview contain AXS-05, AXS-07, AXS-12, and AXS-14. The company was founded by Herriot Tabuteau on January 12, 2012 and is headquartered in New York, NY.

Los Angeles, California--(Newsfile Corp. - August 16, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Axsome Therapeutics, Inc. ("Axsome" or "the Company") (NASDAQ: AXSM) for violations of the securities laws.The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Axsome disclosed on August 9, 2021, that the FDA had found...

ONGOING INVESTIGATION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Axsome Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm

Axsome is down due to two adverse events. The first, rescinding of the BTD for AXS-12, is a non-event.

Axsome: Is The Pullback A Buying Opportunity?

The biotech stock has lost half of its value over the past week.

Why Shares of Axsome Therapeutics Are Down Friday

Los Angeles, California--(Newsfile Corp. - August 13, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Axsome Therapeutics, Inc. ("Axsome" or "the Company") (NASDAQ: AXSM) for violations of the securities laws.The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Axsome disclosed on August 9, 2021, that the FDA had found...

ONGOING INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Axsome Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm

Los Angeles, California--(Newsfile Corp. - August 12, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Axsome Therapeutics, Inc. ("Axsome" or "the Company") (NASDAQ: AXSM) for violations of the securities laws.The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Axsome disclosed on August 9, 2021, that the FDA had found...

ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Axsome Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm

The biotech stock is beaten down but still has potential catalysts ahead.

Is Axsome Therapeutics Stock Ready to Rebound?

NEW YORK--(BUSINESS WIRE)-- #AXSM--Scott+Scott Attorneys at Law LLP Announces Investigation into Axsome Therapeutics Inc. (AXSM)

CORRECTING and REPLACING Scott+Scott Attorneys at Law LLP Announces Investigation into Axsome Therapeutics Inc. (AXSM)

Los Angeles, California--(Newsfile Corp. - August 11, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Axsome Therapeutics, Inc. ("Axsome" or "the Company") (NASDAQ: AXSM) for violations of the securities laws.The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Axsome disclosed on August 9, 2021, that the FDA had found...

INVESTIGATION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Axsome Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm

Scott+Scott Attorneys at Law LLP Announces Investigation into Axsome Therapeutics Inc. (AXSM)

Investors are losing hope in this promising biotech.

Why Axsome Therapeutics Is Plunging Again Today

Axsome Therapeutics (AXSM) reports narrower-than-expected Q2 loss. Yet, share price falls steeply after it notified of a potential delay in the approval of AXS-05 for major depressive disorder

Axsome (AXSM) Q2 Earnings Top, AXS-05 Approval Likely Delayed

Los Angeles, California--(Newsfile Corp. - August 10, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Axsome Therapeutics, Inc. ("Axsome" or "the Company") (NASDAQ: AXSM) for violations of the securities laws.The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Axsome disclosed on August 9, 2021, that the FDA had found...

INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Axsome Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm

LOS ANGELES--(BUSINESS WIRE)---- $AXSM #AXSM--INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Axsome Therapeutics, Inc.

INVESTIGATION ALERT: The Schall Law Firm Announces It Is Investigating Claims Against Axsome Therapeutics, Inc. and Encourages Investors With Losses to Contact the Firm

NEW YORK--(BUSINESS WIRE)--WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Axsome Therapeutics, Inc. (NASDAQ: AXSM) resulting from allegations that Axsome may have issued materially misleading business information to the investing public. SO WHAT: If you purchased Axsome securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangem

AXSM INVESTOR ALERT: Rosen Law Firm Encourages Axsome Therapeutics, Inc. Investors with Losses to Inquire About Class Action Investigation – AXSM

An unexpected regulatory setback is weighing on the biotech's shares today.

Why Axsome Therapeutics Stock Is Crashing Today

Axsome Therapeutics, Inc. (AXSM) CEO Herriot Tabuteau on Q2 2021 Results - Earnings Call Transcript

Wrapped up in its Q2 earnings release, Axsome Therapeutics Inc (NASDAQ: AXSM) said that on July 30, it received an FDA letter for a marketing application for AXS-05 for the treatment of major depressive disorder (MDD). The letter stated that the deficiencies preclude discussion of labeling and post-marketing requirements/commitments at this time.

Axsome Stock Drops To 52-Week Low On FDA Response Letter For Depression Candidate

Axsome Therapeutics (AXSM) has been struggling lately, but the selling pressure may be coming to an end soon.

Axsome Therapeutics (AXSM) Sees Hammer Chart Pattern: Time to Buy?

Company to host conference call today at 8:00 AM Eastern

Axsome Therapeutics Reports Second Quarter 2021 Financial Results and Provides Business Update

AXS-05 significantly delayed the time to relapse of depression compared to placebo (p=0.002, primary endpoint)

Axsome Therapeutics Announces AXS-05 Achieves Primary and Key Secondary Endpoints in the MERIT Phase 2 Trial in Treatment Resistant Depression

Agree Realty

Allegiant Travel Company

Coursera

Chart Industries

Health Catalyst Inc

Karuna Therapeutics Inc

LivePerson

PDC Energy Inc

Q2 Hld

Varonis Systems

A recent pullback has created buying opportunities for many small-cap stocks. Here are the ones the pros are most bullish on.

11 Small-Cap Stocks the Analysts Love for the Rest of 2021

After a fantastic run-up, investors are now losing faith in this emerging biotech's stock.

Is There Any Hope Left for Axsome Therapeutics?

The stock price of Axsome Therapeutics, a biopharmaceutical company focused on developing novel therapies for central nervous system conditions, has seen a 19% drop over the last twenty-one trading days, while it is down 30% over the last year. Last month, we discussed that AXSM stock is more.

Will Axsome Stock Rebound After A 19% Fall In A Month?

The FDA rescinds Breakthrough Therapy designation for Axsome's (AXSM) pipeline candidate, AXS-12. The company is developing AXS-12 for the potential treatment of cataplexy in narcolepsy patients.

Axsome (AXSM) Falls 10% After Losing Breakthrough Therapy Tag

Axsome to host conference call and webcast on Monday, August 9, 2021 at 8:00 AM Eastern Time

News for Axsome Therapeutics Stock (AXSM)